Maria Pia Giannoccaro

Istituto delle Scienze Neurologiche di Bologna

Also affiliated with Ospedale Bellaria, University of Bologna

MedicineNeuroscience

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Doxycycline for the treatment of nodding syndrome: a randomised, placebo-controlled, phase 2 trial”.

Doxycycline for the treatment of nodding syndrome: a randomised, placebo-controlled, phase 2 trial

The Lancet Global Health(2024)10.1016/s2214-109x(24)00102-5

N/A

0.415DataRank · unranked

11 citations

Rodney Ogwang, Ronald Anguzu, Pamela Akun, Albert Ningwa, Catherine Abbo +12 more

HLA-DQB105 subtypes and not DRB110:01 mediates risk in anti-IgLON5 disease

Brain(2024)10.1093/brain/awae048

N/A

0DataRank · unranked

42 citations

Sergio Muñiz‐Castrillo, Lídia Sabater, Vicente Peris-Sempere, Vamsee Mallajosyula, Luo Guo +37 more

Maria Pia Giannoccaro

Indexed papers

Papers

Doxycycline for the treatment of nodding syndrome: a randomised, placebo-controlled, phase 2 trial

HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease

HLA-DQB105 subtypes and not DRB110:01 mediates risk in anti-IgLON5 disease